Saturday, October 05, 2024 10:50:32 PM
mani & J-to,
Thanks for the replies 😶
Click back through the chain of responses and see who was posting baseless statements. I cannot answer every question about the company or speak for the leadership from their perspective as I am only a shareholder. Neither can I answer for everything everyone else chooses to post. I post full-context sources that anyone can evaluate for themselves.
We need to avoid defamatory rumors about the company and its leadership and acknowledge that the long-serving management team are shareholders too.
Market cap can rise rapidly, mani. Nobody is posting false information because forward-looking speculation is by definition unknown. We do have some known aspects of the market that we can consider—the PD1 market is valued in the tens of billions and the global immunotherapy market overall is projected to reach hundreds of billions. Nobody can pinpoint precisely how much of that expanding market NWBO might potentially capture, and an acquisition price would depend on a confluence of factors and circumstances of timing surrounding any such hypothetical deal.
As I often say, it is advisable to seek credible full-context sources such as clinical data, independent licensed physicians, peer-reviewed medical literature, and government regulators.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175186684
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927
Thanks for the replies 😶
Click back through the chain of responses and see who was posting baseless statements. I cannot answer every question about the company or speak for the leadership from their perspective as I am only a shareholder. Neither can I answer for everything everyone else chooses to post. I post full-context sources that anyone can evaluate for themselves.
We need to avoid defamatory rumors about the company and its leadership and acknowledge that the long-serving management team are shareholders too.
Market cap can rise rapidly, mani. Nobody is posting false information because forward-looking speculation is by definition unknown. We do have some known aspects of the market that we can consider—the PD1 market is valued in the tens of billions and the global immunotherapy market overall is projected to reach hundreds of billions. Nobody can pinpoint precisely how much of that expanding market NWBO might potentially capture, and an acquisition price would depend on a confluence of factors and circumstances of timing surrounding any such hypothetical deal.
As I often say, it is advisable to seek credible full-context sources such as clinical data, independent licensed physicians, peer-reviewed medical literature, and government regulators.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175186684
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
